Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fractyl Health (GUTS) Research & Development (2023 - 2025)

Fractyl Health's Research & Development history spans 3 years, with the latest figure at $16.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 18.68% year-over-year to $16.5 million, compared with a TTM value of $74.5 million through Dec 2025, up 5.77%, and an annual FY2025 reading of $74.5 million, up 5.77% over the prior year.
  • Research & Development for Q4 2025 was $16.5 million at Fractyl Health, down from $17.5 million in the prior quarter.
  • The five-year high for Research & Development was $21.2 million in Q2 2025, with the low at $9.1 million in Q2 2023.
  • Average Research & Development over 3 years is $15.3 million, with a median of $16.6 million recorded in 2024.
  • Year-over-year, Research & Development soared 102.56% in 2024 and then dropped 18.68% in 2025.
  • Tracing GUTS's Research & Development over 3 years: stood at $10.2 million in 2023, then surged by 99.5% to $20.3 million in 2024, then decreased by 18.68% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for GUTS's Research & Development are $16.5 million (Q4 2025), $17.5 million (Q3 2025), and $21.2 million (Q2 2025).